Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Silence Therapeutics ADR Representing 3 Ord Shs SLN

Healthcare Biotechnology
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.


NDAQ:SLN - Post by User

Silence Therapeutics ADR Representing 3 Ord Shs
Bullboard Posts
User Avatar Image
(283)
•••
  • whytestocksX
Post by whytestockson Mar 05, 2025 5:00pm
17 Views
Post# 36480931

Silence Therapeutics to Webcast Presentation at the Leerink

Silence Therapeutics to Webcast Presentation at the Leerink This post has been removed in accordance with Community Policy
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities